Actively Recruiting
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)
Led by Brainsway · Updated on 2026-03-24
186
Participants Needed
9
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment. This is a prospective, 6-month, double blind, randomized, controlled, multi-center trial in outpatients recruited in both academic and private research centers. The study population will consist of subjects diagnosed with moderate to severe AUD. The study is comprised of three phases: 1. Pre-study Screening and Baseline Phase 2. Acute Treatment Phase and 3. Maintenance Treatment and Follow up Phase Subjects of all ethnic and gender categories, ages ranging between 18-86 years will be screened for study eligibility according to the inclusion and exclusion criteria. Subjects who meet the eligibility criteria and are willing to sign an informed consent form will be enrolled in the study. The subjects' demographic and baseline characteristics, as well as their overall medical condition will be assessed prior to treatment administration. Eligible patients will be randomized with a 1:1 ratio to one of two study groups (treatment or sham) and stratified by site. Randomization will be employed to avoid bias in the assignment of subjects to treatment group. All subjects will undergo the same treatment regimen, regardless of the assigned treatment group. The acute treatment phase will include 15 treatment visits over a period of 3-5 weeks. The Maintenance Treatment \& Follow-up phase will include one treatment visit per week from the end of the Acute Treatment Phase until the 6 month follow-up visit. At each treatment session, prior to stimulation onset, alcohol related cues will be presented to the subject. After the offset of the alcohol cue presentation, active or sham Deep TMS stimulation will be administered. The study design is directed towards a comparison between active treatment and sham, up to 4 months and 6 months follow-up. Efficacy will be assessed using the primary efficacy measure of the percent heavy drinking days during months 2-4, based on the Time Line Follow Back (TLFB) reporting. Additionally, several subject assessment scales will be used during the course of the study to assess alcohol use and alcohol craving. Safety will be assessed, including monitoring the severity, causality and frequency of all adverse events, vital signs, and physical and neurological examination.
CONDITIONS
Official Title
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects aged 18 to 86 years
- Diagnosed with moderate (4-5 symptoms) to severe (6 or more symptoms) Alcohol Use Disorder according to DSM-5 criteria
- History of at least 24 heavy drinking days in the 90 days before screening (average 8 or more heavy drinking days per month)
- Seeking treatment with a goal to abstain from or reduce heavy drinking
- Able to understand and sign informed consent and follow study requirements
- Passed safety screening questionnaire for transcranial magnetic stimulation
You will not qualify if you...
- Diagnosis of schizophrenia or chronic psychotic disorder
- Present suicidal risk or history of attempted suicide in the past year
- Started medications affecting alcohol consumption within 30 days before screening (e.g., acamprosate, baclofen, disulfiram, naltrexone)
- Significant uncontrolled medical illness (e.g., liver problems, diabetes, heart disease)
- Experiencing acute alcohol withdrawal with CIWA-Ar score above 7
- History of epilepsy or seizures (excluding alcohol withdrawal, ECT-induced, or childhood febrile seizures)
- First-degree relative with seizure history
- High risk of severe violence or suicidality
- Implanted magnetic-sensitive metals near the head or treatment coil
- Cardiac pacemakers or active implantable neurostimulators near treatment coil
- Significant neurological disorders (e.g., brain lesions, stroke, dementia, Parkinson's disease, multiple sclerosis)
- Significant hearing loss
- Previous TMS treatment within one year
- Participation in another device or drug clinical study within 4 weeks
- Unstable psychotherapy treatment or expected changes in therapy during the study
- Known or suspected pregnancy, lactation, or not using contraception if of childbearing potential
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Alpha Neuron LLC
Tuscaloosa, Alabama, United States, 35401
Actively Recruiting
2
Kadima Neuropsychiatry
La Jolla, California, United States, 92037
Actively Recruiting
3
DTMS Center LLC
West Palm Beach, Florida, United States, 33411
Actively Recruiting
4
Rosecrance River North
Chicago, Illinois, United States, 60654
Actively Recruiting
5
ManuMind Interventional Psychiatry
Woodbury, New York, United States, 11797
Actively Recruiting
6
Optimum Wellness and TMS
Columbus, Ohio, United States, 43215
Not Yet Recruiting
7
Active Path Mental Health
Portland, Oregon, United States, 97223
Not Yet Recruiting
8
PsyCare
South Charleston, West Virginia, United States, 25303
Actively Recruiting
9
Soroka Medical Center
Beersheba, Israel, 8410501
Not Yet Recruiting
Research Team
A
Ahava Stein
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here